Daiichi Sankyo

The company announced agreements to use the Oncomine Dx Target Test in drug development programs with Daiichi Sankyo, Takeda, and Spectrum Pharmaceuticals.

HTG will use its EdgeSeq platform to develop a multi-target mRNA assay for Daiichi Sankyo and to profile tumor samples for Centre Léon Bérard.

MolecularMD's assay will be used to select patients for a Phase II clinical trial in Europe to test an unspecified oncology therapy from Daiichi Sankyo.

The large PGx analysis might provide welcome data for those already supportive of genotyping in the context of warfarin, but will it convince detractors?

NEW YORK (GenomeWeb) – Agendia today announced a new deal with Daiichi Sankyo to use Agendia's oncology biomarker technology to evaluate new drugs from the Japanese drug firm currently in clinical trials.

By Adam Bonislawski
Biotech firm KineMed said this week that it has signed a research collaboration agreement with Pfizer to investigate therapies for metabolic diseases, particularly type 2 diabetes.

Roche said this week that European regulators have cleared its Cobas BRAF mutation companion diagnostic for the melanoma drug Zelboraf (vemurafenib).

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – The US Food and Drug Administration has approved Roche's drug and companion diagnostic test for late-stage unresectable melanoma.

Plexxikon is seeking marketing approval for PLX4032 for the treatment of metastatic melanoma in patients harboring the BRAF V600 mutation. Simultaneously, Roche Molecular Diagnostics has submitted a premarket approval application to the FDA for its Cobas 4800 BRAF V600 Mutation Test.

Pages

Magdalena Skipper, the incoming editor-in-chief of Nature, speaks with NPR's Weekend Edition Sunday.

Genetic genealogy has led to an arrest in another cold case, dating back to 1987.

In PLOS this week: mutation in second gene widens clinical symptoms of people with ADD3 mutations, comparative genomic analysis of Pseudovibrio, and more.

Wired reports that 23andMe is trying to bolster its outside collaborations.